Close
Biotechgate
| |

Home Page

News in the Life Sciences Industry

Results 421 - 440 out of 500 displayed.
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21 22  23  24  25 »
Reset 

Getinge Publishes Interim Report for January-September 2018

GOTHENBURG, Sweden, Oct. 18, 2018 /PRNewswire/ -- "We continue to show strong sales growth, but mix effects have a negative effect on our gross margin", says Mattias Perjos, President & CEO at Getinge. "I am not satisfied that despite higher volumes we have only limited productivity effects... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018
Related companies:  Getinge AB | Getinge Infection Control AB

Atrium Medical Corporation, a Subsidiary of Getinge, Divests its Biosurgery Business to HJ Capital 1, the Parent Company of SeCQure Surgical Corporation

GOTHENBURG, Sweden, Oct. 18, 2018 /PRNewswire/ -- Atrium Medical Corporation, a subsidiary of Getinge, has signed an agreement to divest its biosurgery business to HJ Capital 1, the parent company of SeCQure Surgical Corporation, a global medical device company. The deal is expected to close... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018
Related companies:  Getinge AB | Getinge Infection Control AB

Mylan to Release Third Quarter 2018 Financial Results on November 5, 2018

HERTFORDSHIRE, England and PITTSBURGH, Oct. 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018
Related companies:  Mylan (UK)

SYNOSTE Ltd Raises EUR5.1 Million to Launch its Smart Skeletal Deformation Correction Technology

HELSINKI, Finland, October 18, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 18 Oct 2018

Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies

THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable,... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018
Related companies:  Amgen, Inc.

Children with Autism, Developmental Delays are Nearly 50 Percent More Likely to Be Overweight or Obese By Age 5

PHILADELPHIA, Oct. 18, 2018 /PRNewswire/ -- A new study by researchers at Children's Hospital of Philadelphia (CHOP), the University of Pennsylvania and six other centers reveals that children with developmental delays, including Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018
Related companies:  Children's Hospital of Philadelphia

U.S. Medical Cannabis Market Set to Grow with Increasing Global Cannabis Usage

NEW YORK, October 18, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 18 Oct 2018

The Global Cannabis Market is Expected to Grow as Canada Becomes Federally Legal

NEW YORK, October 18, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 18 Oct 2018

Artificial Intelligence (AI) In Healthcare Market to Reach $22.79 Bn, Globally, by 2023 at 48.7% CAGR, Says Allied Market Research

PORTLAND, Oregon, October 18, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 18 Oct 2018
Related companies:  Allied Market Research

Medicover Strengthens Diagnostic Operations in Ukraine

STOCKHOLM, October 18, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 18 Oct 2018

Pharmaceutical Industry Packaging Serialization Lagging as DSCSA Enforcement Deadline Looms

LAWRENCEVILLE, N.J., Oct. 18, 2018 /PRNewswire/ -- Nearly 80 percent of pharmaceutical product packages still do not have a readable barcode with all four required data elements pursuant to the Drug Supply Chain Security Act (DSCSA)- despite the looming November 27, 2018 enforcement deadline... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018
Related companies:  GS1 US

Breast Cancer Radiation Therapy: Understanding The Treatment Options

RESTON, Va., Oct. 18, 2018 /PRNewswire/ -- Breast cancer represents the most common non-skin cancer among women in the United States with over 250,000 new cases each year(1). Most diagnoses represent DCIS (Ductal Carcinoma In Situ) or early stage cancers which can be safely treated with... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018

CytoSorbents to Showcase CytoSorb® at Two Key European Medical Conferences

MONMOUTH JUNCTION, N.J., Oct. 18, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018
Related companies:  CytoSorbents Corporation

Updated Study Analyzes Use and Cost of Orphan Drugs

WASHINGTON, Oct. 18, 2018 /PRNewswire/ -- Despite a record-breaking number of new approvals, orphan drugs remain a nominal part of overall drug spending, accounting for only 9.6% of total sales in the U.S. in 2017, according to a new study released today by the IQVIA Institute. The study was... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018

The Parker Institute for Cancer Immunotherapy Partners with Xyphos Biosciences to Develop Universal Programmable CAR-T Cells for Cancer Treatment

SAN FRANCISCO and SOUTH SAN FRANCISCO, Calif., Oct. 18, 2018 /PRNewswire/ -- The Parker Institute for Cancer Immunotherapy and Xyphos Biosciences today announced a collaboration to create universal CAR-T therapies to treat multiple cancer... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018

Data on Glenmark Pharmaceuticals' GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for the Treatment of Moderate-to-Severe Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference

MAHWAH, N.J., Oct. 18, 2018 /PRNewswire/ -- Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that encore data from a Phase 2a, proof-of-concept study of GBR 830, an investigational treatment in development for moderate-to-severe atopic dermatitis (AD), will be presented... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018
Related companies:  Glenmark Pharmaceuticals Inc. | Glenmark Pharmaceuticals

Medly Pharmacy Expands to New Jersey

NEW YORK, Oct. 18, 2018 /PRNewswire/ -- After a year of astounding growth, Medly Pharmacy is expanding its operations into New Jersey. The pharmacy has one brick and mortar store that it uses as a hub to service all of New York and is opening a store in New Jersey this week to service the entire... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018

Horizon Healthcare Services Inc., New Jersey's Largest Health Insurer, and MAP Health Management Team Up to Improve Addiction Outcomes

AUSTIN, Texas and NEWARK, N.J., Oct. 18, 2018 /PRNewswire/ -- MAP Health Management (MAP) announced today that it has been engaged by Horizon Healthcare Services, Inc. (Horizon), the leading health insurance carrier in New Jersey with more than 3.8 million members, to improve outcomes for members... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018
Related companies:  Pacific Horizon Ventures | Horizon Technology Finance

Grane Rx Expanding to Provide Enhanced PACE Pharmacy Services to the Western United States

DENVER, Oct. 18, 2018 /PRNewswire/ -- Grane Rx announces a significant expansion in the form of a new pharmacy to meet the growing needs of PACE (Programs of All-Inclusive Care for the Elderly) organizations and other special need populations throughout the central and western United States.... Read more ››

By: PR Newswire Association LLC. - 18 Oct 2018

CannTrust and Kindred Launch Sales Team in Canadian Recreational Cannabis Market

Kindred to represent CannTrust products under exclusive agreement

Read more ››
By: PR Newswire Association LLC. - 18 Oct 2018
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21 22  23  24  25 »
to the top ↑